Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 3, 2001, Pages 706-709

  Coyle, E A ^a   Rybak, M J ^a  

^a DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORITAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATION; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; GLYCOPEPTIDES; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 0035118068     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.3.706-709.2001     Document Type: Article

References (12)

1. Moderate resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci
2. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus fuecium
3. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model
4. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
5. In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates
6. Evaluation of bactericidal activities of LY333328, vancomycin, leicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods
7. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniea in Hong Kong
8. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium
9. In vitro activities of an investigational quinolone, glycylecline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium
10. Emergence of vancomycin tolerance in Streptococcus pneumoniae
11. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus